Peritoneal Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 5-6 business days
DelveInsight’s, “Peritoneal cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Peritoneal cancer: Overview
The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs. When cancer spreads from other organs, it is considered advanced and denote Stage IV disease in most cases. Complications related to peritoneal metastases include: Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension, Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines, Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect the kidney function. The diagnosis of peritoneal cancer can be difficult. Imaging (such as CT or MRI scans), needle drainage of ascitic fluid for analysis, keyhole surgery, or a combination of these may be required to confirm the diagnosis of peritoneal metastases. Treatment of peritoneal cancer depends on the stage of cancer, where the primary tumor started, how far it has spread, and the patient’s overall health. Surgery, chemotherapy, radiotherapy, and targeted therapy.
'Peritoneal cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal cancer pipeline landscape is provided which includes the disease overview and Peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peritoneal cancer Emerging Drugs
Further product details are provided in the report……..
Peritoneal cancer: Therapeutic Assessment
This segment of the report provides insights about the different Peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:
Peritoneal cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal cancer drugs.
Peritoneal cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Peritoneal cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Peritoneal cancer: Overview
The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs. When cancer spreads from other organs, it is considered advanced and denote Stage IV disease in most cases. Complications related to peritoneal metastases include: Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension, Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines, Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect the kidney function. The diagnosis of peritoneal cancer can be difficult. Imaging (such as CT or MRI scans), needle drainage of ascitic fluid for analysis, keyhole surgery, or a combination of these may be required to confirm the diagnosis of peritoneal metastases. Treatment of peritoneal cancer depends on the stage of cancer, where the primary tumor started, how far it has spread, and the patient’s overall health. Surgery, chemotherapy, radiotherapy, and targeted therapy.
'Peritoneal cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal cancer pipeline landscape is provided which includes the disease overview and Peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal cancer.
This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peritoneal cancer Emerging Drugs
- Mirvetuximab soravtansine: ImmunoGen
- Pembrolizumab: Merck & Co
- DCVAC/OvCa: SOTIO
- PF-06873600: Pfizer
Further product details are provided in the report……..
Peritoneal cancer: Therapeutic Assessment
This segment of the report provides insights about the different Peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peritoneal cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Peritoneal cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal cancer drugs.
Peritoneal cancer Report Insights
- Peritoneal cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peritoneal cancer drugs?
- How many Peritoneal cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peritoneal cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Peritoneal cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Mirvetuximab soravtansine: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
PF-06873600: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
ART0380: Artios Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Peritoneal cancer Key Companies
Peritoneal cancer Key Products
Peritoneal cancer- Unmet Needs
Peritoneal cancer- Market Drivers and Barriers
Peritoneal cancer- Future Perspectives and Conclusion
Peritoneal cancer Analyst Views
Peritoneal cancer Key Companies
Appendix
Executive Summary
Peritoneal cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Mirvetuximab soravtansine: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
PF-06873600: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
ART0380: Artios Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Peritoneal cancer Key Companies
Peritoneal cancer Key Products
Peritoneal cancer- Unmet Needs
Peritoneal cancer- Market Drivers and Barriers
Peritoneal cancer- Future Perspectives and Conclusion
Peritoneal cancer Analyst Views
Peritoneal cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Peritoneal cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Peritoneal cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Peritoneal cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Peritoneal cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
